Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates.

Pyridyl aminothiazoles comprise a novel class of ATP-competitive Chk1 inhibitors with excellent inhibitory potential. Modification of the core with ethylenediamine amides provides compounds with low picomolar potency and very high residence times. Investigation of binding parameters of such compounds using X-ray crystallography and molecular dynamics simulations revealed multiple hydrogen bonds to the enzyme backbone as well as stabilization of the conserved water molecules network in the hydrophobic binding region.

[1]  Ian Collins,et al.  Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases. , 2010, Bioorganic & medicinal chemistry letters.

[2]  Andrew Potter,et al.  Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening. , 2006, Bioorganic & medicinal chemistry.

[3]  Nicolas Foloppe,et al.  Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification. , 2005, Bioorganic & medicinal chemistry.

[4]  J. Bartek,et al.  p53‐dependent G1 arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors , 2010, Cell proliferation.

[5]  A. Sancar,et al.  Reconstitution of a human ATR-mediated checkpoint response to damaged DNA , 2007, Proceedings of the National Academy of Sciences.

[6]  F. Bunz,et al.  Checkpoint bypass and cell viability , 2010, Cell cycle.

[7]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[8]  D. Conrad,et al.  Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways , 2003, Cancer biology & therapy.

[9]  Cynthia Winter,et al.  RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma , 2011, Proceedings of the National Academy of Sciences.

[10]  W. F. Hoffman,et al.  Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics. , 2002, Bioorganic & medicinal chemistry letters.

[11]  Yun Dai,et al.  New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network , 2010, Clinical Cancer Research.

[12]  M. Prudhomme.  Novel checkpoint 1 inhibitors. , 2006, Recent patents on anti-cancer drug discovery.

[13]  Jiri Bartek,et al.  Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.

[14]  Michael Reilly,et al.  Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[15]  Synthesis and evaluation of 5-substituted 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as check point 1 kinase inhibitors. , 2010, Bioorganic & medicinal chemistry.

[16]  Michael B Yaffe,et al.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.

[17]  T. Helleday,et al.  Chk1 promotes replication fork progression by controlling replication initiation , 2010, Proceedings of the National Academy of Sciences.

[18]  Stephen Green,et al.  AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies , 2008, Molecular Cancer Therapeutics.

[19]  Lawrence C Kuo,et al.  3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6. , 2006, Bioorganic & medicinal chemistry letters.

[20]  S. Fesik,et al.  Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. , 2003, Molecular cancer therapeutics.

[21]  D. Heimbrook,et al.  Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel. , 2004, Journal of medicinal chemistry.

[22]  M. Broggini,et al.  Chk1, but not Chk2 , is Involved in the Cellular Response to DNA Damaging Agents: Differential Activity in Cells Expressing, or not, p53 , 2004, Cell cycle.

[23]  Georgia B McGaughey,et al.  The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase. , 2004, Bioorganic & medicinal chemistry letters.

[24]  Laura Sepp-Lorenzino,et al.  Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase. , 2007, Bioorganic & medicinal chemistry letters.